raltegravir-potassium and Conjunctivitis--Viral

To determine the effects of orally administered raltegravir in cats with experimentally induced ocular and respiratory feline herpesvirus-1 (FHV-1) infection.. 14 healthy 6-month-old unvaccinated specific pathogen-free cats.. On day 0, all cats were experimentally inoculated by topical application of 0.1 mL of a solution containing 10. Cats in both groups developed moderate to severe conjunctivitis and ulcerative keratitis characteristic of FHV-1 infection. Median duration of FHV-1 shedding was shorter and signs of ocular and respiratory disease were less severe for raltegravir-treated cats than for vehicle-treated cats. However, the mean conjunctival FHV-1 titer and corneal epithelial leukocyte count did not differ between the 2 groups.. Results suggested orally administered raltegravir might be effective for alleviation of ocular and respiratory signs of FHV-1 infection in cats. (

Topics: Animals; Antiviral Agents; Cat Diseases; Cats; Conjunctivitis, Viral; Herpesviridae Infections; Raltegravir Potassium; Random Allocation; Respiratory Tract Infections; Single-Blind Method; Specific Pathogen-Free Organisms; Varicellovirus